BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21264827)

  • 21. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
    Aisner J; Belani CP; Kearns C; Conley B; Hiponia D; Engstrom C; Zuhowski E; Egorin MJ
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):17-21. PubMed ID: 7481856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
    Langer CJ
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):108-16. PubMed ID: 10210549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
    Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
    Jeremić B; Miličić B; Milisavljevic S
    Cancer; 2011 Jul; 117(13):2995-3003. PubMed ID: 21692056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
    Socinski MA; Clark JA; Halle J; Steagall A; Kaluzny B; Rosenman JG
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-117-S12-122. PubMed ID: 9331135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
    Chang JY; Zhang X; Wang X; Kang Y; Riley B; Bilton S; Mohan R; Komaki R; Cox JD
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1087-96. PubMed ID: 16682145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
    Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
    Choy H; DeVore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; LaPorte K; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-21-S12-26. PubMed ID: 9331115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
    Choy H; Nabid A; Stea B; Scott C; Roa W; Kleinberg L; Ayoub J; Smith C; Souhami L; Hamburg S; Spanos W; Kreisman H; Boyd AP; Cagnoni PJ; Curran WJ
    J Clin Oncol; 2005 Sep; 23(25):5918-28. PubMed ID: 16135463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study.
    Comella G; Frasci G; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Ruffolo P; Comella P
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-113-S12-116. PubMed ID: 9331134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy.
    Wei X; Liu HH; Tucker SL; Liao Z; Hu C; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):100-7. PubMed ID: 16839700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
    Schild SE; McGinnis WL; Graham D; Hillman S; Fitch TR; Northfelt D; Garces YI; Shahidi H; Tschetter LK; Schaefer PL; Adjei A; Jett J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1106-11. PubMed ID: 16730134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.
    Harris JP; Murphy JD; Hanlon AL; Le QT; Loo BW; Diehn M
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):872-84. PubMed ID: 24495591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer.
    Kobayashi H; Uno T; Isobe K; Ueno N; Watanabe M; Harada R; Takiguchi Y; Tatsumi K; Ito H
    Jpn J Clin Oncol; 2010 May; 40(5):464-9. PubMed ID: 20085905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
    Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
    Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
    J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer.
    Jazieh AR; Younas A; Safa M; Redmond K; Buncher R; Howington J
    Cancer Invest; 2007 Aug; 25(5):294-8. PubMed ID: 17661203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.